---
id: acr-lupus-nephritis-2024
title: "ACR 2024 Guideline for the Management of Lupus Nephritis"
short_title: "ACR Lupus Nephritis 2024"

organization: American College of Rheumatology
collaborators: null
country: US
url: https://www.rheumatology.org/guidelines
doi: null
pmid: null
open_access: true

specialty: rheumatology
guideline_type: clinical-practice
evidence_system: ACR GRADE
conditions:
  - lupus nephritis
  - SLE nephritis
  - glomerulonephritis
tags:
  - mycophenolate mofetil
  - cyclophosphamide
  - belimumab
  - voclosporin
  - hydroxychloroquine

publication_date: 2024-03-01
previous_version_date: 2024-01-01
status: current
supersedes: null
superseded_by: null

pdf_path: null
has_pdf: false
last_reviewed: 2025-12-26
---

## Scope
2024 ACR guideline update on the management of lupus nephritis (LN) in adults.

## Key Recommendations

### Diagnosis
- Kidney biopsy is recommended for patients with SLE and clinical evidence of nephritis (proteinuria, hematuria, rising creatinine).
- ISN/RPS classification: Class I-VI.

### General Measures (All LN Patients)
- **Hydroxychloroquine**: Strongly recommended for all patients unless contraindicated.
- **ACE inhibitor / ARB**: For proteinuria and BP control.
- **SGLT2 Inhibitors**: Consider for renal protection, especially with significant proteinuria.
- Immunizations, VTE prophylaxis during high disease activity.

### Induction Therapy (Class III/IV ± V)

#### Standard Regimens
- **Mycophenolate Mofetil (MMF) + Glucocorticoids**: Preferred for most patients.
- **Cyclophosphamide (NIH or Euro-Lupus protocol) + Glucocorticoids**: Alternative; effective for severe disease.

#### Add-On Therapies (Recommended)
- **Belimumab (Anti-BLyS)**: Add to MMF or cyclophosphamide-based induction. Improves renal response, reduces flares.
- **Voclosporin (Calcineurin Inhibitor)**: Add to MMF + low-dose steroids. Improves complete renal response rates.

### Class V (Membranous) LN
- If nephrotic-range proteinuria: Treat with MMF + glucocorticoids ± belimumab or voclosporin.
- If subnephrotic proteinuria and normal GFR: ACEi/ARB, hydroxychloroquine, close monitoring.

### Maintenance Therapy
- **MMF or Azathioprine** after successful induction.
- Continue hydroxychloroquine.
- Gradual steroid taper.

### Refractory LN
- Rituximab may be considered.
- Switch induction agents.

### Goals
- Achieve complete renal response (proteinuria <0.5 g/day, stable GFR).
- Avoid flares and minimize steroid exposure.
